Orchid Pharma enter tech transfer pact to make key cephalosporin intermediate

Orchid Pharma, the Chennai-based drug maker on Tuesday said it has entered into a technology transfer agreement with a leading multinational biotechnology company for its fermentation based ‘7ACA project’ under the production linked incentive (PLI) scheme.

The company didn't disclose the name of the biotechnology firm or further details of the agreement.
Orchid Pharma announced that its wholly-owned subsidiary, Orchid Bio Pharma, has received approval to manufacture ‘7-ACA’ with a capacity of 1,000 tonne per annum. 7-ACA (7-aminocephalosporanic acid) is
a key intermediate for the synthesis of semisynthetic cephalosporin antibiotics. It is produced from the fermentation product cephalosporin C.